HIF1alpha-Targeted Therapy for Diabetes and Obesity
Posted Jun 02 2011 8:00pm
Description of Invention: This technology describes the use of hypoxia inducible factor 1 alpha (HIF1alpha) inhibitors for the reduction of body weight and treatment of diabetes.
In obesity, the rapid expansion of adipose tissue outpaces the oxygen supply, resulting in hypoxia. HIF1alpha, a transcription factor that plays an essential role in cellular and systemic responses to low oxygen levels, is activated in these tissues, and causes inflammation that has been linked to insulin resistance and other metabolic dysfunction.
To examine the role of hypoxia in obesity and insulin resistance, investigators at the National Cancer Institute disrupted the HIF1alpha gene (or its dimerization partner, the HIF1beta) in the adipose tissue of transgenic mice, and found that these mice were protected from obesity and insulin resistance when fed a high-fat (western) diet. In further experiments, administration of an HIF1alpha inhibitor to wild-type mice achieved similar reductions in fat mass and insulin resistance, as well as other indicators of metabolic disease. Thus, HIF1alpha inhibitors represent promising new leads for obesity and diabetes therapeutics.
Applications: HIF1alpha-targeted therapies for type 2 diabetes and obesity
Development Status: Proof of concept has been demonstrated in mouse models.
Collaborative Research Opportunity: The Center for Cancer Research, Laboratory of Metabolism (LM), is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIF1alpha inhibitors that can be used for the treatment of obesity and type 2 diabetes. The LM will be willing to collaborate with parties to evaluate potential inhibitors using the HIF1alpha adipose-specific knockout mice. Please contact John Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Internal Medicine Internal Medicine - Therapeutics
For Licensing Information Please Contact: Tara Kirby Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: tk200h@nih.gov Phone: 301-435-4426 Fax: 301-402-0220
Description of Invention:
This technology describes the use of hypoxia inducible factor 1 alpha (HIF1alpha) inhibitors for the reduction of body weight and treatment of diabetes.
In obesity, the rapid expansion of adipose tissue outpaces the oxygen supply, resulting in hypoxia. HIF1alpha, a transcription factor that plays an essential role in cellular and systemic responses to low oxygen levels, is activated in these tissues, and causes inflammation that has been linked to insulin resistance and other metabolic dysfunction.
To examine the role of hypoxia in obesity and insulin resistance, investigators at the National Cancer Institute disrupted the HIF1alpha gene (or its dimerization partner, the HIF1beta) in the adipose tissue of transgenic mice, and found that these mice were protected from obesity and insulin resistance when fed a high-fat (western) diet. In further experiments, administration of an HIF1alpha inhibitor to wild-type mice achieved similar reductions in fat mass and insulin resistance, as well as other indicators of metabolic disease. Thus, HIF1alpha inhibitors represent promising new leads for obesity and diabetes therapeutics.
Applications:
HIF1alpha-targeted therapies for type 2 diabetes and obesity
Development Status:
Proof of concept has been demonstrated in mouse models.
Inventors:
Frank J Gonzalez (NCI)
Changtao Jiang (NCI)
Patent Status:
HHS, Reference No. E-018-2011/0
US, Application No. 61/423,936 filed 16 Dec 2010
Relevant Publication:
Licensing Status:
Available for licensing.
Collaborative Research Opportunity:
The Center for Cancer Research, Laboratory of Metabolism (LM), is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIF1alpha inhibitors that can be used for the treatment of obesity and type 2 diabetes. The LM will be willing to collaborate with parties to evaluate potential inhibitors using the HIF1alpha adipose-specific knockout mice. Please contact John Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
For Licensing Information Please Contact:
Tara Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tk200h@nih.gov
Phone: 301-435-4426
Fax: 301-402-0220
Ref No: 2261
Updated: 06/2011